Amplia Therapeutics (ASX:ATX) has started dosing the first patient in Cohort 3 of its Phase 1b/2a ACCENT clinical trial, testing the FAK inhibitor AMP945 in pancreatic cancer.

Cohort 3 will include three patients receiving an increased dose of the drug after a safety committee deemed the dose used in Cohort 2 to be safe and well-tolerated.

Amplia Therapeutics says the ACCENT trial is designed to assess the safety and efficacy of AMP945 in combination with nab-paclitaxel and gemcitabine in pancreatic cancer patients.

Its share price is up 6% at 2:29pm AEST.